An Investigator Initiated Multi-center Phase 4 Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients With Inadequate Effects From Previous Treatment (IKE-03, Switching Study)
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms IKE-03-SWITCHING
- 04 Mar 2021 New trial record